The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $3.56 in the prior trading day, Eagle Pharmaceuticals Inc (NASDAQ: EGRX) closed at $2.14, down -39.89%. In other words, the price has decreased by -$39.89 from its previous closing price. On the day, 4.66 million shares were traded. EGRX stock price reached its highest trading level at $2.8 during the session, while it also had its lowest trading level at $1.8.
Ratios:
Our goal is to gain a better understanding of EGRX by taking a closer look at its different ratios.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on August 10, 2023, Downgraded its rating to Underweight and sets its target price to $17 from $26 previously.
On August 09, 2023, Piper Sandler Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $26 to $17.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’23 when Tarriff Scott sold 10,925 shares for $13.82 per share. The transaction valued at 150,984 led to the insider holds 556,141 shares of the business.
Tarriff Scott sold 10,694 shares of EGRX for $148,326 on Nov 02 ’23. The CEO now owns 545,447 shares after completing the transaction at $13.87 per share. On Oct 03 ’23, another insider, Tarriff Scott, who serves as the CEO of the company, sold 10,734 shares for $14.46 each. As a result, the insider received 155,174 and left with 567,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EGRX now has a Market Capitalization of 27730550 and an Enterprise Value of 84892120. Its current Enterprise Value per Revenue stands at 0.33 whereas that against EBITDA is 1.362.
Stock Price History:
Over the past 52 weeks, EGRX has reached a high of $15.69, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -51.71%, while the 200-Day Moving Average is calculated to be -56.02%.
Shares Statistics:
The stock has traded on average 105.08K shares per day over the past 3-months and 561950 shares per day over the last 10 days, according to various share statistics. A total of 12.99M shares are outstanding, with a floating share count of 11.43M. Insiders hold about 12.02% of the company’s shares, while institutions hold 76.76% stake in the company. Shares short for EGRX as of 1726185600 were 350531 with a Short Ratio of 3.34, compared to 1723680000 on 484164. Therefore, it implies a Short% of Shares Outstanding of 350531 and a Short% of Float of 4.19.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
1 analysts predict $62.83M in revenue for the current quarter. It ranges from a high estimate of $62.83M to a low estimate of $62.83M. As of the current estimate, Eagle Pharmaceuticals Inc’s year-ago sales were $62.08MFor the next quarter, 1 analysts are estimating revenue of $64.51M. There is a high estimate of $64.51M for the next quarter, whereas the lowest estimate is $64.51M.
A total of 1 analysts have provided revenue estimates for EGRX’s current fiscal year. The highest revenue estimate was $258.29M, while the lowest revenue estimate was $258.29M, resulting in an average revenue estimate of $258.29M. In the same quarter a year ago, actual revenue was $316.61MBased on 1 analysts’ estimates, the company’s revenue will be $224.81M in the next fiscal year. The high estimate is $224.81M and the low estimate is $224.81M.
